Introduction/Background To evaluate the mismatch repair (MMR) protein expression in endometrial cancer and to assess their association with clinico-pathologic outcomes.
Methodology A retrospective review of the clinico-pathologic data and clinical outcomes was performed on patients who were treated for endometrial cancer at a single center between 2014 and 2018. For the study analysis, patients with results for MMR protein immunohistochemistry were included. MMR-deficient (MMR-d) was defined as absence of expression in any of the 4 MMR proteins (MLH1, MSH2, MSH6, and PMS2). Clinical and pathologic outcomes were compared according to the MMR status.
Results A total of 146 endometrial cancer patients with available MMR expression data were included. Of these, 41 patients (28.1%) showed absence of MMR protein expression (MMR-d). Compared with MMR-proficient (MMR-p) patients, the MMR-d patients had higher rate of pelvic and/or para-aortic lymph node metastasis and lymphovascular space invasion (p=0.011 and p=0.015, respectively). However, other clinico-pathologic variables, including stage, grade, histologic subtype, and depth of invasion, were not associated with MMR status. During the median follow-up period of 18.2 months (1–39.4), there was no difference in progression-free survival between MMR-p and MMR-d patients (p=0.181).
Conclusion MMR defects were associated with higher rate of lymphovascular space invasion and lymph node metastasis. However, other prognostic factors and survival outcomes were not different between MMR-p and MMR-d patients.
Disclosure Nothing to disclose.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.